BACKGROUND: Differential protein targeting by HIV-specific CD8 T cells is associated with disparate plasma viral loads; however, it is unclear if the quality of these responses differs depending upon the specificity of the targeted epitopes. METHODS: We examined HIV-specific CD8 T-cell responses in HIV-infected adolescents carrying either an HLA class I allele associated with a favorable prognosis (HLA-B*57) or an allele associated with usual disease progression (HLA-B*35 or HLA-B*53) using interferon-gamma ELISpot and ICS assays. RESULTS: In an interferon-gamma ELISpot assay, p24 was the dominant protein targeted by B*57 carriers while responses to Nef dominated in B*35 or B*53 positive carriers. This differential protein targeting did not change during 4 years of follow-up. In these chronically infected adolescents, there were no significant differences in the quality of the immunodominant T-cell responses between the B*57 and B*35/B*53 carriers as measured by peptide avidity, degranulation, and immune memory markers. There was a trend towards higher expression of interleukin-2 from B*57-KF11 restricted CD8 T cells although this difference was not significant. Nevertheless both B*57 and B*35/53-restricted responses were relatively potent as reflected by the propensity of CD8 T cells to escape in p24 and Nef, respectively. CONCLUSIONS: Differential protein targeting rather than the quality of T-cell responses appears to be a major distinguishing feature of HIV-specific CD8 T cells induced in B*57 carriers. These data suggest that viral fitness costs associated with CD8 T-cell pressure is an important factor determining differences in the viral load among HIV-infected patients.
BACKGROUND: Differential protein targeting by HIV-specific CD8 T cells is associated with disparate plasma viral loads; however, it is unclear if the quality of these responses differs depending upon the specificity of the targeted epitopes. METHODS: We examined HIV-specific CD8 T-cell responses in HIV-infected adolescents carrying either an HLA class I allele associated with a favorable prognosis (HLA-B*57) or an allele associated with usual disease progression (HLA-B*35 or HLA-B*53) using interferon-gamma ELISpot and ICS assays. RESULTS: In an interferon-gamma ELISpot assay, p24 was the dominant protein targeted by B*57 carriers while responses to Nef dominated in B*35 or B*53 positive carriers. This differential protein targeting did not change during 4 years of follow-up. In these chronically infected adolescents, there were no significant differences in the quality of the immunodominant T-cell responses between the B*57 and B*35/B*53 carriers as measured by peptide avidity, degranulation, and immune memory markers. There was a trend towards higher expression of interleukin-2 from B*57-KF11 restricted CD8 T cells although this difference was not significant. Nevertheless both B*57 and B*35/53-restricted responses were relatively potent as reflected by the propensity of CD8 T cells to escape in p24 and Nef, respectively. CONCLUSIONS: Differential protein targeting rather than the quality of T-cell responses appears to be a major distinguishing feature of HIV-specific CD8 T cells induced in B*57 carriers. These data suggest that viral fitness costs associated with CD8 T-cell pressure is an important factor determining differences in the viral load among HIV-infectedpatients.
Authors: Marcus Altfeld; Marylyn M Addo; Eric S Rosenberg; Frederick M Hecht; Paul K Lee; Martin Vogel; Xu G Yu; Rika Draenert; Mary N Johnston; Daryld Strick; Todd M Allen; Margaret E Feeney; James O Kahn; Rafick P Sekaly; Jay A Levy; Jürgen K Rockstroh; Philip J Goulder; Bruce D Walker Journal: AIDS Date: 2003-12-05 Impact factor: 4.177
Authors: Thomas C Friedrich; Elizabeth J Dodds; Levi J Yant; Lara Vojnov; Richard Rudersdorf; Candice Cullen; David T Evans; Ronald C Desrosiers; Bianca R Mothé; John Sidney; Alessandro Sette; Kevin Kunstman; Steven Wolinsky; Michael Piatak; Jeffrey Lifson; Austin L Hughes; Nancy Wilson; David H O'Connor; David I Watkins Journal: Nat Med Date: 2004-02-15 Impact factor: 53.440
Authors: Steffanie Sabbaj; Anju Bansal; G Douglas Ritter; Christopher Perkins; Bradley H Edwards; Ethan Gough; Jianming Tang; James J Szinger; Bette Korber; Craig M Wilson; Richard A Kaslow; Mark J Mulligan; Paul A Goepfert Journal: J Acquir Immune Defic Syndr Date: 2003-08-01 Impact factor: 3.731
Authors: Anju Bansal; Steffanie Sabbaj; Bradley H Edwards; Doug Ritter; Christopher Perkins; James Tang; James J Szinger; Heidi Weiss; Paul A Goepfert; Bette Korber; Craig M Wilson; Richard A Kaslow; Mark J Mulligan Journal: AIDS Res Hum Retroviruses Date: 2003-11 Impact factor: 2.205
Authors: Jianming Tang; Craig M Wilson; Shreelatha Meleth; Angela Myracle; Elena Lobashevsky; Mark J Mulligan; Steven D Douglas; Bette Korber; Sten H Vermund; Richard A Kaslow Journal: AIDS Date: 2002-11-22 Impact factor: 4.177
Authors: Stephen A Migueles; Alisha C Laborico; Hiromi Imamichi; W Lesley Shupert; Cassandra Royce; Mary McLaughlin; Linda Ehler; Julia Metcalf; Shuying Liu; Claire W Hallahan; Mark Connors Journal: J Virol Date: 2003-06 Impact factor: 5.103
Authors: A J Leslie; K J Pfafferott; P Chetty; R Draenert; M M Addo; M Feeney; Y Tang; E C Holmes; T Allen; J G Prado; M Altfeld; C Brander; C Dixon; D Ramduth; P Jeena; S A Thomas; A St John; T A Roach; B Kupfer; G Luzzi; A Edwards; G Taylor; H Lyall; G Tudor-Williams; V Novelli; J Martinez-Picado; P Kiepiela; B D Walker; P J R Goulder Journal: Nat Med Date: 2004-02-08 Impact factor: 53.440
Authors: R Draenert; C L Verrill; Y Tang; T M Allen; A G Wurcel; M Boczanowski; A Lechner; A Y Kim; T Suscovich; N V Brown; M M Addo; B D Walker Journal: J Virol Date: 2004-01 Impact factor: 5.103
Authors: V Novitsky; P Gilbert; T Peter; M F McLane; S Gaolekwe; N Rybak; I Thior; T Ndung'u; R Marlink; T H Lee; M Essex Journal: J Virol Date: 2003-01 Impact factor: 5.103
Authors: Nicholas J Steers; Jeffrey R Currier; Gustavo H Kijak; Robert C di Targiani; Ashima Saxena; Mary A Marovich; Jerome H Kim; Nelson L Michael; Carl R Alving; Mangala Rao Journal: J Virol Date: 2010-11-24 Impact factor: 5.103
Authors: Sushma Boppana; Sarah Sterrett; Jacob Files; Kai Qin; Andrew Fiore-Gartland; Kristen W Cohen; Stephen C De Rosa; Anju Bansal; Paul A Goepfert Journal: J Infect Dis Date: 2019-10-08 Impact factor: 5.226
Authors: Heather A Prentice; Matthew A Price; Travis R Porter; Emmanuel Cormier; Michael J Mugavero; Anatoli Kamali; Etienne Karita; Shabir Lakhi; Eduard J Sanders; Omu Anzala; Pauli N Amornkul; Susan Allen; Eric Hunter; Richard A Kaslow; Jill Gilmour; Jianming Tang Journal: Virology Date: 2013-12-12 Impact factor: 3.616
Authors: Jianming Tang; Rakhi Malhotra; Wei Song; Ilene Brill; Liangyuan Hu; Paul K Farmer; Joseph Mulenga; Susan Allen; Eric Hunter; Richard A Kaslow Journal: PLoS One Date: 2010-03-10 Impact factor: 3.240
Authors: Anju Bansal; Tiffanie Mann; Sarah Sterrett; Binghao J Peng; Anne Bet; Jonathan M Carlson; Paul A Goepfert Journal: J Acquir Immune Defic Syndr Date: 2015-09-01 Impact factor: 3.731
Authors: Anju Bansal; Jonathan Carlson; Jiyu Yan; Olusimidele T Akinsiku; Malinda Schaefer; Steffanie Sabbaj; Anne Bet; David N Levy; Sonya Heath; Jianming Tang; Richard A Kaslow; Bruce D Walker; Thumbi Ndung'u; Philip J Goulder; David Heckerman; Eric Hunter; Paul A Goepfert Journal: J Exp Med Date: 2010-01-11 Impact factor: 14.307